Molecule News and Research

RSS

Aratana Therapeutics announces acquisition of Okapi Sciences NV

Aratana Therapeutics, Inc., a biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for pets, today announced that it has acquired Okapi Sciences NV, a Belgium-based company with a proprietary pet therapeutics antiviral platform and five clinical/development stage candidates for treating important viral diseases.

6 Jan 2014

Study uncovers how enzymes could be used to identify predisposition to ROS-related diseases

A UT Arlington chemist doing National Science Foundation-funded research on enzymes that regulate human biology has uncovered characteristics that could be used to identify predisposition to conditions such as heart disease, diabetic ulcers and some types of cancer.

6 Jan 2014

Scientists reveal atomic-level view of genetic defect that causes myotonic dystrophy type 2

Scientists from the Florida campus of The Scripps Research Institute have revealed an atomic-level view of a genetic defect that causes a form of muscular dystrophy, myotonic dystrophy type 2, and have used this information to design drug candidates with potential to counter those defects—and reverse the disease.

6 Jan 2014

Uneven distribution of cellular organelles during cell division may enhance bacterial population's survival

Although a population of bacteria may be genetically identical, individual bacteria within that population can act in radically different ways.

3 Jan 2014

AstraZeneca to take over Probiodrug's CDK9 inhibitor program

Probiodrug AG announced today the transfer of its experimental cyclin-dependent kinase 9 inhibitor program to AstraZeneca. The transaction includes the sale to AstraZeneca of a lead molecule and back-up compounds with the associated intellectual property. CDK9, which has been implicated in the transcriptional regulation of genes involved in proliferation and inflammation, is a promising target for the treatment of both cancer and inflammatory diseases.

3 Jan 2014

Study indicates that smoking disrupts circadian clock function in both lungs and brain

As if cancer, heart disease and other diseases were not enough motivation to make quitting smoking your New Year's resolution, here's another wake-up call: New research published in the January 2014 issue of The FASEB Journal suggests that smoking disrupts the circadian clock function in both the lungs and the brain.

3 Jan 2014

Biologists discover effective strategy that could prevent immune system from rejecting grafts

Biologists at UC San Diego have discovered an effective strategy that could prevent the human immune system from rejecting the grafts derived from human embryonic stem cells, a major problem now limiting the development of human stem cell therapies.

3 Jan 2014

Molecule produced by brain acts as natural defence mechanism against cannabis

Two INSERM research teams led by Pier Vincenzo Piazza and Giovanni Marsicano (INSERM Unit 862 "Neurocentre Magendie" in Bordeaux) recently discovered that pregnenolone, a molecule produced by the brain, acts as a natural defence mechanism against the harmful effects of cannabis in animals.

3 Jan 2014

Research confirms superior antitumor activity of novel anticancer agent FL118

A team led by Fengzhi Li, PhD, of Roswell Park Cancer Institute has reported significant new findings regarding the chemical structure of the novel anticancer agent FL118. The research, which included comparative analysis of the agent and several similar compounds, confirms the broad, superior antitumor activity of FL118 and suggests promising directions for further studies.

2 Jan 2014

Study finds way to boost corneal transplant acceptance rate

For the estimated 10 percent of patients whose bodies reject a corneal transplant, the odds of a second transplant succeeding are poor. All that could change, however, based on a UT Southwestern Medical Center study that has found a way to boost the corneal transplant acceptance rate.

31 Dec 2013

Researchers provide new insights into how common cold virus infects

On average, each of us catches a cold two to three times a year. However, how the common cold virus actually infects us is only partly understood. Researchers from the Max F. Perutz Laboratories of the Medical University of Vienna and the University of Vienna, in collaboration with two Spanish groups, have now provided new insights into this process.

30 Dec 2013

CF101 drug fails to meet primary efficacy endpoint in phase III study for Dry Eye Syndrome

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that its subsidiary OphthaliX Inc. released results from a 24 week, placebo-controlled phase III study involving 237 patients with moderate-to-severe Dry Eye Syndrome who were treated with its licensed drug CF101, an A3 adenosine receptor agonist.

30 Dec 2013

Combination of NGF microspheres and chitosan conduits exhibit better effects in repairing facial nerve injury

The chitosan molecule can promote nerve cell adherence and growth along the surface of the material. It can enhance the adherence and influx of Schwann cells, thus encouraging the growth of axons.

28 Dec 2013

Protein responsible for excretion of copper in body cells utilizes unique transport mechanism

We are fundamentally dependent on the presence of copper in the cells of the body. Copper is actually part of the body's energy conversion and protective mechanisms against oxygen radicals, as well as part of the immune system, and it also has great importance for the formation of e.g. hormones and neurotransmitters.

28 Dec 2013

Unprecedented, atom-scale simulation of G protein-coupled receptor site's transformation

Roughly 40 percent of all medications act on cells' G protein-coupled receptors (GPCRs). One of these receptors, beta 2 adrenergic receptor site (B2AR), naturally transforms between two base configurations; knowing the precise location of each of approximately 4,000 atoms is crucial for ensuring a snug fit between it and the drug.

28 Dec 2013

THRIL could be novel biomarker for immune activation, potential target for inflammatory diseases

Sanford-Burnham Medical Research Institute scientists have discovered a new molecule that forms when certain white blood cells-macrophages-are stimulated in response to pathogens.

27 Dec 2013

Can-Fite reports positive results from CF101 Phase IIb study for rheumatoid arthritis

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced results from a 12-week, placebo-controlled Phase IIb study involving 79 patients with active rheumatoid arthritis ("RA") for its proprietary drug CF101, an A3 adenosine receptor ("A3AR") agonist.

23 Dec 2013

Small molecule nonsense suppression strategy for aniridia-associated defects

Congenital aniridia is a progressive disease that is associated with improper development of eye structures as well as abnormalities in the brain and pancreas. A variety of nonsense mutations in the PAX6 gene are linked with aniridia; however, despite understanding the genetic basis of the disease, few treatment and prevention strategies are available.

22 Dec 2013

Engineered immune cells show antitumor activity in two patients with advanced cancers

Engineered immune cells, called CARTmeso cells, designed to direct antitumor immune responses toward tumors that carry a protein called mesothelin, showed antitumor activity in two patients with advanced cancers that had not responded to prior treatments, according to a study published in Cancer Immunology Research, a journal of the American Association for Cancer Research.

22 Dec 2013

Scientists discover new way to stop malaria parasites from multiplying

Scientists have taken an important step towards new malaria treatments by identifying a way to stop malaria parasites from multiplying.

22 Dec 2013

Molecule News and Research

Aratana Therapeutics announces acquisition of Okapi Sciences NV

Study uncovers how enzymes could be used to identify predisposition to ROS-related diseases

Scientists reveal atomic-level view of genetic defect that causes myotonic dystrophy type 2

Uneven distribution of cellular organelles during cell division may enhance bacterial population's survival

AstraZeneca to take over Probiodrug's CDK9 inhibitor program

Study indicates that smoking disrupts circadian clock function in both lungs and brain

Biologists discover effective strategy that could prevent immune system from rejecting grafts

Molecule produced by brain acts as natural defence mechanism against cannabis

Research confirms superior antitumor activity of novel anticancer agent FL118

Study finds way to boost corneal transplant acceptance rate

Researchers provide new insights into how common cold virus infects

CF101 drug fails to meet primary efficacy endpoint in phase III study for Dry Eye Syndrome

Combination of NGF microspheres and chitosan conduits exhibit better effects in repairing facial nerve injury

Protein responsible for excretion of copper in body cells utilizes unique transport mechanism

Unprecedented, atom-scale simulation of G protein-coupled receptor site's transformation

THRIL could be novel biomarker for immune activation, potential target for inflammatory diseases

Can-Fite reports positive results from CF101 Phase IIb study for rheumatoid arthritis

Small molecule nonsense suppression strategy for aniridia-associated defects

Engineered immune cells show antitumor activity in two patients with advanced cancers

Scientists discover new way to stop malaria parasites from multiplying

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News